Obseva SA (NASDAQ:OBSV) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 557,500 shares, a growth of 125.5% from the July 31st total of 247,200 shares. Based on an average daily trading volume, of 46,500 shares, the short-interest ratio is presently 12.0 days. Currently, 2.5% of the company’s shares are short sold.
A number of institutional investors and hedge funds have recently bought and sold shares of OBSV. Capital Investment Advisory Services LLC bought a new position in Obseva in the 2nd quarter valued at $40,000. Fosun International Ltd purchased a new stake in shares of Obseva during the first quarter valued at $2,494,000. Geode Capital Management LLC purchased a new stake in shares of Obseva during the fourth quarter valued at $159,000. Morgan Stanley grew its holdings in shares of Obseva by 358.6% in the second quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after purchasing an additional 2,424 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Obseva by 263.6% in the second quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after purchasing an additional 2,372 shares during the last quarter. Institutional investors own 63.97% of the company’s stock.
A number of brokerages recently issued reports on OBSV. Royal Bank of Canada restated a “buy” rating on shares of Obseva in a research report on Sunday, August 11th. Credit Suisse Group cut their price objective on shares of Obseva from $24.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday, July 29th. Wedbush reissued an “outperform” rating and issued a $38.00 target price on shares of Obseva in a research note on Thursday, July 18th. HC Wainwright restated a “buy” rating and issued a $44.00 target price on shares of Obseva in a report on Wednesday, September 4th. Finally, Zacks Investment Research lowered shares of Obseva from a “hold” rating to a “sell” rating in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $28.00.
Obseva (NASDAQ:OBSV) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.22). Research analysts predict that Obseva will post -2.99 earnings per share for the current year.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.